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1. Introduction 
Hemocytopenia is very common in patients with cirrhotic portal hypertension. These patients 
experience complications of monolineage or multi-lineage peripheral cytopenias. However, 
the range of variation of these cytopenias is unclear, and the question of whether they affect all 
patients remains uncertain. In general, it is believed that such cytopenias are caused by 
hypersplenism; however, this may not always be the case as numerous factors that cause 
hemocytopenia exist, and hypersplenism is only one of them. Patients with hypersplenism 
experience hemocytopenia, but not all cytopenias are caused by hypersplenism.  
Can cytopenias be graded? How do cytopenias affect prognosis? According to the 
observation of clinical cases, cytopenias may, in fact, influence prognosis. These questions 
will be discussed in this chapter, which integrates clinical data from 366 cases investigated 
by the author.  
2. Changes of peripheral blood cells 
It has been accepted that “all patients with splenomegaly due to cirrhotic portal hypertension 
will manifest cytopenias in peripheral blood [1]; however, certain limitations were noticed in 
the traditional opinion by the author after studying clinical data from 366 cases.  
This study included 250 male patients and 116 female patients (a total of 366 patients), and 
the ratio of males to females was 2.2:1. The patients’ ages ranged from 5 to 79 years, with an 
average of 43 years. All the patients had hepatic cirrhosis and an enlarged spleen. The 
average spleen size was 224mm×159mm×95mm, as measured by B ultrasound or CT scan. 
Upper gastrointestinal imaging and gastroscopy revealed that there were medium-to-severe 
varices in the distal esophagus and gastric fundus (Figure 1). Seventy-four patients (20.2%) 
were hospitalized for gastrointestinal hemorrhage, and 248 (67.8%) patients had previously 
experienced hemorrhaging.Thirty-six patients (9.8%) had a normal blood cell count and 330 
patients had peripheral cytopenias, in which mono-lineage cytopenias accounted for 30% 
(99/330), bi-lineage cytopenias accounted for 35.8% (118/330) and tri-lineage cytopenias 
accounted for 34.2% (113/330).The range of variation of hemocytopenia is listed in Table 1. 
Two-hundred ninety-seven cases underwent bone marrow aspiration, in which 155 cases 
(52.2%) showed moderate proliferation. The remaining cases were normal.  
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Fig. 1. severe varices in the distal esophagus and gastric fundus. 
 
Item N % WBC (×109/L) RBC (×1012/L) PLT (×109/L) 
Pancytopenia 113 34.2 
2.35±0.76 
(median 2.36) 
2.99±0.64 
(median 3.00) 
58.6±19.8 
(median 57.8) 
WBC+PLT 30 9.1 
2.76±0.71 
(median 2.73) 
---- 
56.9±21.2 
(median 53.8) 
RBC+PLT 48 14.5 ---- 
2.83±0.20 
(median2.63) 
67.2±21.3 
(median 62.5) 
WBC+RBC 40 12.1 
2.85±0.76 
(median 2.68) 
3.11±0.30 
(median 2.96) 
----- 
PLT 27 8.2 ---- ---- 
66.2±23.3 
(median 61.7) 
WBC 14 4.2 
2.98±0.65 
(median 2.82) 
----- ----- 
RBC 58 17.6 ---- 
2.71±0.50 
(median 2.56) 
---- 
Note: The difference in WBC was significant between Group 1 and Group 2, 4 and 6 (P＜0.05), and not 
significant between Group 2 and Group 4 and 6 (P＞0.05); The difference in RBC was significant 
between Group 1 and Group 7, between Group 3 and Group 4, and between Group 4 and Group 7 
(P＜0.05), not significant between Group 1 and Group 3 and 4 (P＞0.05), and not significant between 
Group 3 and Group 7 (P＞0.05); And the difference in PLT was not significant when the 4 groups were 
compared (P＞0.05, F=1.61). 
Table 1. Hemocyte decrease (mean±SEM) in 330 cases ( x ±s)  
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3. Causes of hemocytopenia in peripheral blood 
There are numerous causes for cytopenias in patients with hepatocirrhotic portal 
hypertension, including the toxic effects of hepatic viruses and alcohol on the bone marrow, 
hypofunctioning of the liver [2], splenomegaly, hypersplenism, gastrointestinal bleeding, and 
hematopoietic dysfunction caused by malnutrition. In most cases, cytopenias are caused by 
multiple factors.  
3.1 Toxic effects of hepatic virus 
Hepatic viruses can directly suppress the differentiation and proliferation of hemopoietic 
stem cells and progenitor cells [3]. (2) Hepatic virus can cause disorders of cellular immunity 
and humoral immunity in vivo, to compromise the body’s capacity to eliminate the viruses. 
The constant presence of viruses damages the hemopoietic functioning of the bone marrow 
[4]. (3) Viruses can impair the activity of bone marrow stromal cells to reduce the secretion of 
cytokines and to affect the proliferation of hemopoietic cells. (4) During pathogenesis caused 
by cytokines, the increase in the γ- interferon level and decrease in the interleukin-6 and 
erythropoietin levels, can affect the proliferation of hemopoietic cells [5]. The hepatitis B 
virus (HBV) and hepatitis C virus (HCV) can suppress the bone marrow, and affect the 
growth of all karyocytes in the bone marrow. This may lead to hypoplastic anemia, and 
patients must undergo a bone marrow transplant to survive.  
The liver and bone marrow are target tissues of HBV. This virus can kill or injure 
hemopoietic cells directly, causing myelosuppression, and leading to leukopenia and 
reduction in the detoxification ability of the liver. This renders the body more sensitive to 
certain medicines, toxins and environmental pollutants, and cause hypofunctioning of bone 
marrow hematopoiesis. Leukopenia further damages immunity to cause the active 
replication of HBV, forming a vicious cycle. Currently, antiviral therapy is the first choice 
for chronic hepatitis B patients; however, antiviral medications also lead to 
myelosuppression. Therefore, monitoring leukocytes in the peripheral blood is conducive to 
the regulation of antiviral therapy. If the leukocyte count is lower than 2×109/L, antiviral 
therapy should be discontinued. Both HBV and HCV can induce suppression of the 
precursor cells of the bone marrow, and affect the lymph cells, causing lymphopenia and 
hypofunctioning of the bone marrow.  
3.2 Toxic effects of alcohol 
In the 1980s, studies of patients with alcoholic liver disease reported that neutrophil 
granulocytes demonstrated retarded growth and delayed release in the bone marrow. Later 
studies showed increased apoptosis of neutrophil granulocytes. Patients with end-stage 
cirrhosis complicated with neutropenia underwent Granulocyte-Macrophage Colony 
Stimulating Factor (GM-CSF) therapy for 7 days, and the leukocyte count increased more 
than 100%. However, the increased leukocytes could not be destroyed in the spleen, for no 
leukocyte fragments were found in the spleen. Ethanol can suppress or stimulate cellular 
proliferation, but in most cases, it suppresses cellular growth and increases cytotoxic effects. 
Its mechanism includes retarded cellular proliferation and induced apoptosis and necrosis [6-
8]. A foreign study reported [9] that long-term alcoholism could cause abnormalities in the 
bone marrow and peripheral blood. In that study, 91% patients manifested changes in the 
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peripheral blood including granulopenia, thrombopenia, etc., and changes in bone marrow 
included highly-differentiated hemopoietic tissue and myelofibrosis. Long-term alcohol 
consumption can reduce the absorption of folic acid and vitamin B12, which impairs the 
synthesis of erythrocytes. Djordjevic et al [10] believed both that hepatic viruses and 
alcoholism were able to cause cytopenias.  
3.3 Hypofunctioning of liver 
Hypofunctioning of the liver reduces degradation of toxic metabolites by liver cells; in this 
case, the liver cannot detoxify the toxins that suppress the bone marrow, thus affecting 
hemopoietic function. The incidence of liver disease combined with thrombopenia is 15% - 
70%. It is usually at mild or moderate level, and its severity is a prognostic indicator. In liver 
diseases, thrombopenia is closely related to hepatocirrhosis, anti-platelet autoantibodies [11], 
bone marrow suppression caused by HBV and HCV, and toxic effects from excessive 
alcohol consumption [12]. The discovery of thrombopoietin (TPO) in 1994 ushered in a new 
era in the study of cirrhotic thrombopenia. TPO is almost exclusively produced in liver cells; 
a small proportion of TPO is produced in the kidneys, bone marrow stromal cells and 
muscle. The production of TPO depends on the function and amount of liver cells. In 
cirrhosis, functional liver cells become less able to decrease the secretion of TPO. A study by 
Wolber et al. [13], of cirrhotic patients developing from the compensation to decompensation 
stage, demonstrated that the expression or serum level of TPO changed from an increase to 
a decrease, and that the platelet count decreased gradually. The decrease in liver function, to 
some extent, was related to hemocytopenia and bone marrow dysfunction. Forbes et al. [14] 
suggested that hepatic exogenous myofibroblasts played an important role in hepatic 
fibrosis. In hepatic fibrosis, bone marrow stem cells differentiate into hepatic endothelial 
parenchymal cells but not into myofibroblasts. This indicates that the change in hemopoietic 
function and inner environment of the bone marrow might be somehow related to or 
interactive with the occurrence and development of hepatic fibrosis or even hepatic 
cirrhosis. These observations suggest that changes in the bone marrow of cirrhotic patients 
do not result from one single factor but a combination of multiple factors, with a 
complicated regulation mechanism. The changes in bone marrow might be directly or 
indirectly related to the severity of hepatic cirrhosis and changes in liver or spleen function. 
Their relationship and the detailed mechanism remain to be further explored. Solving this 
puzzle will be of significant importance to clinical practice.  
3.4 Splenomegaly and hypersplenism 
Hypersplenism is secondary to splenomegaly. Two mechanisms for splenomegaly caused 
by liver diseases exist. The first mechanism is expansionary splenomegaly, including 
congestive splenomegaly caused by increased venous pressure and hyperemic 
splenomegaly caused by increased splenic arterial flow; the former is the main cause. The 
second mechanism is hypertrophic splenomegaly, including: (1) Hepatic virus antigen and 
exogenous antigens unprocessed by the liver due to a shunting procedure, can stimulate the 
spleen and lead to hypertrophy of the immune tissue in the spleen (splenic corpuscle, 
periarterial lymphatic sheath, marginal zone). (2) In hepatic cirrhosis, increased necrotic 
cells and hypofunctioning of the hepatic reticuloendothelial system promote compensatory 
hypertrophy and lead to hyperfunctioning of the splenic reticuloendothelial system. (3) 
Increased intrasplenic pressure, stasis of blood circulation, change in the metabolic 
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environment and other factors can cause fibroplastic proliferation. Generally speaking, 
intrasplenic immune tissues show obvious hypertrophy during hepatitis, and middle or end 
stage cirrhotic patients mainly manifest splenic sinus dilation, hypertrophy of 
reticuloendothelial system and fibrous tissues.  
Currently, there are several hypotheses concerning the mechanism of cytopenia: (1) The 
hypothesis of intrasplenic trapping[15]: After the formation of splenomegaly, blood volume 
in the spleen increases, and a great number of leukocytes, erythrocytes and platelets are 
trapped in the spleen. The ratio of trapped hemocytes compared with that in the normal 
spleen is 5.5- to 20-fold, resulting in hemocytopenia in the peripheral blood. (2) The 
hypothesis of cytophagy: There are a large number of mononuclear-macrophages in the 
spleen. Under pathological circumstances, mononuclear-macrophages demonstrate 
hyperfunctioning in cytophagy and destruction of hemocytes, especially erythrocytes [16]. 
Recently, a study using erythrocyte creatine (EC), the life-span sensitive marker of 
erythrocytes, revealed that the EC level was significantly increased in patients with 
splenomegaly due to post-necrotic cirrhosis compared with patients with hepatic cirrhosis 
with normal spleens (P<0.05). In addition, the same was observed compared with the 
normal control group but without a significant difference [17]. This suggested that 
splenomegaly accelerated the destruction of erythrocytes and the determination of the EC 
value could be used to evaluate the severity of cirrhotic splenomegaly [18]. (3) The spleen can 
produce excessive “splenic hormones” to suppress the hemopoietic function of the bone 
marrow, and accelerate the destruction of and trap produced hemocytes to prevent them 
from entering into blood circulation [19]. (4) The hypothesis of autoimmunity: The spleen is a 
large lymph organ that produces antibodies. Antigens unprocessed by the liver enter the 
marginal zones of splenic lymph follicles (splenic nodule) and activate the pro-lymphocytes 
and plasma cells to generate antibodies. These antibodies can destroy hemocytes causing 
hemocytopenia in the peripheral blood.  
3.5 Gastrointestinal bleeding 
Gastroesophageal fundus varices bleeding is a common complication for patients with 
cirrhotic portal hypertension. Gastrointestinal bleeding of any cause can directly lead to a 
decreased amount of hemocytes in the effective circulatory blood volume.  
Chronic gastrointestinal bleeding can result in iron, folic acid and vitamin B12 deficiencies, 
and insufficient material for the synthesis of erythrocytes. Massive loss of erythrocytes can 
lead to anemia in patients. A Cr51 labeled-erythrocyte test demonstrated that only 20% of 
patients with cirrhosis complicated with anemia had increased erythrocytes in their spleens.  
3.6 Malnutrition 
Portal hypertensive gastropathy can cause malabsorption of hematopoietic growth factors 
and non-visible loss of nutrients necessary for hematopoiesis. Additionally, the lack of iron, 
folic acid and vitamin B12 results in insufficient materials for the synthesis of erythrocytes, 
leading to decreased hematopoiesis.  
The significance of exploring the causes of hemocytopenia in the peripheral blood in the 
patients with cirrhotic portal hypertension lies in its guidance for treatment and evaluation 
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for therapeutic effects. If hemocytopenia is caused by splenomegaly or hypersplenism, 
whether monolineage or multi-lineage, the decreased hemocytes will rise significantly after 
a splenectomy (P<0.01). The most sensitive is hemocyte is the platelet, which will increase 
half an hour after the operation, and reach the highest level in 2 weeks; afterwards it will 
decrease gradually and remain at a normal level. Leukocytes and erythrocytes would 
increase following the platelets. Hemocytopenia in the peripheral blood caused by non-
splenic factors does not lead to a definite increase in hemocytes after splenectomy.  
4. Hemocytopenia in peripheral blood and its prognosis  
The postoperative prognosis was classified as cured, improved or dead. There were few 
cases without any changes. In this analysis, cured meant meeting the following criteria: the 
disappearance of ascites, abdominal distension and hemorrhage, blood cell count increase 
and recovery, improvement in liver function, no severe postoperative complications, and 
meeting the criteria for being discharged from the hospital. On the other hand, dead meant 
that the patients died during hospitalization, or that the patients in critical condition died 
one week after early discharge from the hospital, as requested by the relatives. All others 
were considered improved. Comparison of the therapeutic effect between each mono-
lineage cytopenia group is shown in Table 2. Comparison of the therapeutic effect between 
mono-lineage cytopenia and bi-lineage and comparisons of the therapeutic effect between 
the mono-lineage cytopenia and bi-lineage cytopenias, the mono-lineage cytopenia and 
multi-lineage cytopenias are shown in Table3 and Table 4, respectively. 
 
Group Grade 
Case 
number 
Therapeutic effect χ2, P value 
Cured (%) Improved (%) Dead (%) 
WBC 
(×109/L, 
N=14) 
<2 1 1 (100) 0 0  
 
χ2=1.478, 
P=0.478 
 
2-3 10 6(60) 4 (40) 0 
3-4 3 1 (33.3) 2 (66.7) 0 
RBC 
(×1012/L, 
N=58) 
<2 4 3 (75) 0 1 (25) χ2=10.908 
P=0.028<0.05 
2-3 20 16 (80) 2 (10) 2 (10) 
3-4 34 16 (47.1) 16(47.1) 2 (5.8) 
PLT 
(×109/L, 
N=27) 
<30 3 1 (33.3) 2 (66.7) 0 χ2=2.220, 
P=0.695 
30-50 1 1 (100) 0 0 
50-100 23 15 (65.2) 7 (30.4) 1 (4.4) 
HB 
(hemoglobin ) 
(×g/L, 
N=366) 
<30 78 32 (41) 39 (50) 7(9) 
χ2=4.236, 
P=0.375 
30-70 52 28 (53.8) 20 (38.5) 4 (7.7) 
>70 236 122 (51.7) 89 (37.7) 25 (10.6) 
Note: Among the four mono-lineage peripheral cytopenia groups, only the RBC group demonstrated a 
significant difference in intra-group comparison (p<0.05); comparison among the four groups revealed 
no significant difference (P>0.05).  
Table 2. Comparison of the therapeutic effect between each mono-lineage peripheral 
cytopenia group 
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Table 2 shows that only the RBC group demonstrated a significant difference (P＜0.05) in 
the intra-group comparison among the mono-lineage cytopenia groups. According to Table 
3 and Table4, there were significant differences (P＜0.05) in the therapeutic effects between 
mono-lineage cytopenias and multi-lineage cytopenias, indicating that the more severe the 
cytopenia, the worse the therapeutic results appeared to be. 
For the multi-lineage cytopenias(Table5), a multiple linear regression analysis was applied, 
and results revealed that thrombocytopenia was the major factor (P＜0.005) influencing the 
therapeutic effect, while leukopenia, erythropenia and decreased hemoglobin showed no 
statistical significance, and should not be considered. Erythropenia showed significant 
differences in the intra-group comparison of mono-lineage cytopenias, but no difference 
compared to other mono-lineage cytopenia groups. This was possibly due to the small 
sample size in the mono-lineage cytopenia groups. Leukopenia showed no significant 
difference in the univariate analysis or the multivariate analysis, and had no influence on 
the therapeutic results. For example, 2 patients recovered and were discharged from the 
hospital though their leukocyte count was lower than 1×109/L; this may have been because 
they had no serious postoperative infection. Theoretically, anemia is related to the 
prognosis, but in this research it showed no statistical significance in the univariate analysis 
or the multivariate analysis; the reason for this may have been because the blood 
transfusions before and during operation had a favorable effect on the blood condition. 
Although thrombocytopenia had no statistical significance in the univariate analysis, in the 
multiple linear regression analysis it was indicated to be the most important influential 
factor with the increase in case load.  
 
Item 
Total case 
number 
Therapeutic effect χ2, P value 
Cured (%) Improved (%) Dead (%) 
Mono-lineage 
cytopenia 
99 60 (60.6%) 33 (33.3%) 6 (6.1%) χ2=7.446,  
P=0.024 Bi-lineage 
cytopenia 
118 51 (43.2%) 51 (43.2%) 16 (13.6%) 
Table 3. Comparison of the therapeutic effect between the mono-lineage cytopenia and bi-
lineage cytopenia 
 
Item 
Total case 
number 
Therapeutic effect χ2, P value 
Cured (%) Improved (%) Dead (%) 
Mono-lineage 
cytopenia 
99 60 (60.6) 33 (33.3) 6 (6.1) χ2=7.819, 
P=0.02 Multi-lineage 
cytopenia 
231 102 (44.2) 102 (44.2) 27 (11.6) 
Table 4. Comparison of the therapeutic effect between the mono-lineage cytopenia and tri-
lineage cytopenia 
Thrombocytopenia is a significant and common complication in posthepatitic cirrhotic 
portal hypertension[20-21]; it is related to not only retention of blood cell in the spleen, blood 
cell aggregation and enhanced phagocytosis of macrophages[22], but also HBV infection, and 
compensation and regulation of marrow[23]. Djordevic et al[10]. proposed that extreme 
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thrombocytopenia was life-threatening. A PLT count of < 30×109/L can cause variceal 
hemorrhaging in the distal esophagus and gastric fundus, and intraoperative and 
postoperative massive wound hemorrhaging, which can be life-threatening. Therefore, PLT 
transfusions should be performed before an operation to increase the PLT count to 50×109/L to 
ensure the safety of the patient. Cui et al[24]. reported that PLT transfusions combined with 
plasma fibrinogen transfusions led to better results. In some cases, after transfusion of 12-24 
units of PLT, the PLT count did not increase obviously, or decreased to the previous lowest 
count after 1-2 days. These types of patients are suitable for splenectomy[25]. Mastuura et 
al.[26]suggested that the excessive postoperative PLT count was also a life-threatening factor, so 
the condition of the patient should be closely monitored[27-28] when there is excessive platelet 
count, appropriate treatment should be administrated immediately.  
 
Item T value P value 
PLT 2.827 .005 
RBC -.439 .661 
WBC 1.516 .130 
HB 0.628 0.531 
Constant 1.395 .000 
Note: Regression equation Ŷ =1.395+0.151 PLT 
Table 5. Multiple linear regression analysis of blood cells in 366 cases 
5. Grading of hemocytopenia 
In 1907, Chauffard proposed the term ‘hypersplenism’ for the first time[29]. After further 
research, in 1949, Doan[30] proposed the criteria for hypersplenism: 1. enlarged spleen 2. 
mono-lineage or multi-lineage cytopenias 3. normal or proliferative bone marrow 4. 
disappearance of the pathological changes in the blood components after splenectomy. 
While these four criteria are indispensable for the diagnosis of hypersplenism, peripheral 
cytopenia and an increase and recovery in blood cell count after a splenectomy are the major 
criteria for assessing hypersplenism due to cirrhotic portal hypertension. This is because 
splenomegaly in itself is a necessary criterion for the cirrhotic portal hypertension. 
It is of vital significance to formulate a grading method, like the Child-Pugh Classification 
for liver function, to evaluate hypersplenism. However, grading of hypersplenism is 
extremely difficult for many reasons. 1) Some patients show decreased monolineage 
cytopenias and others show bi-lineage cytopenias. Even patients with pancytopenia barely 
meet the grading criteria. 2) There are many causes of hemocytopenia, but no examination 
can ascertain whether it is caused by splenomegaly or hypersplenism. A definite diagnosis 
would be made only when hemocytes returned to a normal level after splenectomy.  
Although grading of hypersplenism is difficult, hemocytopenia could be graded. According 
to a multiple linear regression, thrombopenia is the major factor influencing the effect of 
surgery. The 330 cases of cytopenia scores were mainly based on thrombocytopenia 
combined with erythropenia, as well as clinical experience (leukopenia). Scoring was as 
follows: PLT＞50<100×109/L was scored as 1 point, 30-50×109/L was scored as 2 points, 
<30×109/L was scored as 3 points; RBC 3-4×1012/L was scored as 0 points, and 
RBC<3×1012/L was scored as 1 point; WBC 2-4×109/L was scored as 0 points, and 
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WBC<2×109/L was scored as 1 point. Except for 36 cases with normal blood cell counts and 
69 cases with 0 points, the influences of scores on postoperative prognoses in 261 cases are 
shown in Table 6 (totally 105 cases). There were significant differences between the 3 groups 
(P＜0.05). Therefore, peripheral cytopenias were graded as mild (<2), medium (2-3) or 
severe (>3) (Table 7). 
Thus, only cytopenias can be graded. In the present study, the cases were scored and 
graded based on the accumulated scores. The scoring criteria used in this study were: 
1.Analytical results of multiple linear regression: F value obtained from multiple linear 
regression equation was 7.993 (P＜0.005), indicating that multiple linear regression was 
applicable. The equation Ŷ=1.395+0.151PLT indicated that thrombocytopenia was the 
major influential factor for postoperative prognosis. Therefore, according to the severity 
of the thrombocytopenia, 1 to 3 points was scored. 2. Intra-group comparison of 
erythropenia showed a significant difference (P＜0.05), so an RBC count ≤3×1012/L was 
scored as 1 point. 3. According to clinical experience, leukopenia can cause severe 
infection and lead to undesirable effects. A WBC of count ≤2×109/L was scored as 1 point, 
though leukopenia showed no statistical significance in either the univariate analysis or 
multivariate analysis. A total score of ＜2 points indicated mild cytopenia, 2-3 points 
indicated medium cytopenia and ＞3 points indicated severe cytopenia. If cytopenias are 
caused by hypersplenism, this grading standard could also be used for grading 
hypersplenism or as a reference. 
 
Item 
Total case 
number 
Therapeutic effect χ2, P value 
Cured (%) Improved (%) Death (%) 
1 point 136 80 (58.8%) 43(31.6%) 13 (9.6%) χ2=10.163 
P=0.034 
2-3 points 95 41 (43.2%) 44 (46.3%) 10 (10.5%) 
4-5 points 30 10 (33.3%) 15 (50%) 5 (16.7%) 
Table 6. Comparison of the influence of different scores on the therapeutic effect 
 
Item Mild Medium Severe 
PLT 
(Score) 
>50 
1 
30-50 
2 
<30 
3 
RBC 
(Score) 
>3 
0 
2-3 
1 
<2 
1 
WBC 
(Score) 
>3 
0 
2-3 
0 
<2 
1 
Total score ＜2 2-3 ＞3 
Table 7. Grading of peripheral cytopenias (hypersplenism) 
Cytopenia grading could facilitate clinical practice in various aspects, including assessing 
the disease condition, representation and academic communication, communication with 
patients and their relatives to resolve or avoid medical disputes, choosing a suitable 
treatment plan (for example, splenectomy is suitable for severe cytopenia or hypersplenism) 
and taking preventive methods before an operation16 to increase the curative rate.  
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6. Treatment  
As to the patients with splenomegaly due to cirrhotic portal hypertension complicated with 
hemocytopenia in the peripheral blood, treatment should aim at both the causes and clinical 
symptoms, that is, the principle of treating the branch and the root simultaneously.  
6.1 Treatment of causes of disease 
 Antiviral treatment: Patients with severe viral infection should take antiviral medicine 
for an extended time, and should be constantly monitored to protect liver function.  
 Avoid drinking alcohol: Patients with alcoholic cirrhosis and post-hepatic cirrhosis 
should avoid drinking alcohol; otherwise, disease conditions may deteriorate. In 
addition, medications that affect liver function should be avoided.  
 Correcting malnutrition: Patients with obvious emaciation and malabsorption should 
replenish nutrients, such as iron, folic acid and vitamin B12 to avoid a shortage of 
materials for the synthesis of erythrocytes. Additionally, patients should undergo blood 
transfusions to treat anemia and increase the hemochrome level.  
6.2 Treatment of symptoms 
Different treatments should be applied according to the severity of the disease. Patients with 
mild hemocytopenia should be under close observation; for patients with moderate 
hemocytopenia, blood components or whole blood transfusions should be applied as well as 
hemocyte boosting medications. In severe cases, a splenectomy in the patients with 
splenomegaly should be considered. Theoretically, splenic arterial embolization can also 
achieve the same effect as a splenectomy, but this procedure tends to cause splenic 
infarction, splenic necrosis, splenic abscess and high fever. This method should only be 
attempted by experienced physicians.  
In recent years, autologous stem cell transplantation has achieved good results in the 
treatment of cirrhotic portal hypertension complicated with hemocytopenia in the 
peripheral blood [17], but more research is needed to further its application in clinics.  
6.3 Treatment of both the branch and root: Treating the causes and the clinical 
symptoms  
1. Gastrointestinal bleeding: Gastrointestinal bleeding is not only a cause of 
hemocytopenia in peripheral blood, but also a complication of cytopenia. It is of vital 
importance to treat gastrointestinal bleeding; treatment measures include blood 
transfusion, fluid infusion, intravenous injection of antacid, administration of 
somatostatin (sandostatin and stilamin), endoscopic loop ligation of bleeding areas, 
sclerotherapy, and so on. Lecleire et al. [31] demonstrated that the success rate of 
endoscopic treatment could reach 80%. Intervention embolization can also be applied. 
Selective embolization can stop the bleeding in most cases. In recent years, with the 
improvement of coaxial catheter and embolization material, super-selective 
angiography and transcatheter embolization (SATE) is regarded as a safe and effective 
method to treat gastrointestinal hemorrhage[32]. It should be the first choice for patients 
suffering from post-operational massive hemorrhage, especially for the elderly or the 
sick. If the intervention fails, surgery should be performed.  
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If massive hemorrhage cannot be stopped using the measures mentioned above, emergency 
surgery should be performed, including pericardial devascularization and/or placement of 
a transjugular intrahepatic portal systemic shunt.  
2. Liver transplantation: Schuppan et al. [33] concluded that liver transplantation was an 
effective method to treat cirrhotic portal hypertension, as it not only corrected liver 
problems, but also cured portal hypertension, and was likely an effective way to treat 
hemocytopenia. After transplantation, the TPO level increases immediately. In 2 or 3 
days, the TPO level can be 5-10 times the level it was before the surgery. In about 6 
days, the platelet count returns to the normal range, and anemia is corrected. Therefore, 
liver transplantation can treat both the branch and root simultaneously.  
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